Search details
1.
Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.
J Inherit Metab Dis
; 44(6): 1463-1480, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34418116
2.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Neurol
; 23(7): 687-699, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38782015
3.
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet Neurol
; 22(10): 900-911, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37739573
4.
A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001-2004.
BMC Public Health
; 9: 18, 2009 Jan 14.
Article
in English
| MEDLINE | ID: mdl-19144172
5.
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
Biol Psychiatry
; 82(1): 8-16, 2017 07 01.
Article
in English
| MEDLINE | ID: mdl-28117049
6.
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Neurol
; 16(7): 513-522, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28460889
7.
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Lancet Psychiatry
; 3(12): 1115-1128, 2016 Dec.
Article
in English
| MEDLINE | ID: mdl-27816567
8.
AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
Br J Pharmacol
; 172(5): 1292-304, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25363835
9.
Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.
Schizophr Res
; 162(1-3): 169-74, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25579053
10.
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
Psychiatry Res
; 218(1-2): 219-24, 2014 Aug 15.
Article
in English
| MEDLINE | ID: mdl-24809242
11.
Carboxy-terminated oligo(ethylene glycol)-alkane phosphate: synthesis and self-assembly on titanium oxide surfaces.
Langmuir
; 23(2): 377-81, 2007 Jan 16.
Article
in English
| MEDLINE | ID: mdl-17209580
Results
1 -
11
de 11
1
Next >
>>